Table 2.

Partial correlation of serum TRAIL prior to infliximab infusion (at time 0) with selected continuous variables adjusted for age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity, and hypertension) in 30 patients with ankylosing spondylitis.

Variable	TRAIL (time 0)
	r	P
Age at the onset of symptoms	−0.026	0.90
Disease duration*	−0.011	0.96
BMI*	0.042	0.84
Systolic blood pressure*	0.039	0.85
Diastolic blood pressure*	0.087	0.66
BASDAI*	0.089	0.66
VAS spinal pain*	0.135	0.50
ESR* (natural-log-transformed)	0.018	0.93
CRP* (natural-log-transformed)	−0.080	0.69
ESR** (natural-log-transformed)	0.045	0.83
CRP** (natural-log-transformed)	0.011	0.96
T o t a l   c h o l e s t e r o l* (natural-log-transformed)	−0.393	0.04
HDL cholesterol* (natural-log-transformed)	−0.111	0.58
L D L   c h o l e s t e r o l* (natural-log-transformed)	−0.452	0.02
Atherogenic index* (total cholesterol/HDL)	−0.180	0.38
Triglycerides* (natural-log-transformed)	0.185	0.36
Serum glucose* (natural-log-transformed)	−0.092	0.65
HOMA-IR at time0*	0.368	0.06
QUICKI at time0*	−0.440	0.02
Resistin at time 0	−0.427	0.05
Adiponectin at time 0	−0.009	0.97
Leptin at time 0	0.069	0.74
Visfatin at time 0	0.048	0.81
Angpt-2 at time 0	−0.055	0.79
Apelin at time 0	0.373	0.06
ADMA at time 0	−0.058	0.78
Gelsolin at time 0	0.173	0.39
OPN at time 0	−0.372	0.06
RBP-4 at time 0	0.318	0.11
Osteoprotegerin at time 0	0.044	0.83

*At the time of the study. **At the time of disease diagnosis.

ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin 2; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; LDL: low-density lipoprotein; OPN: osteopontin; QUICKI: quantitative insulin sensitivity check index; RBP-4: retinol-binding protein 4; VAS: visual analogue scale.